Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 64

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies

Deinhardt-Emmer, Stefanie, Chousterman, Benjamin G, Schefold, Joerg C, Flohé, Stefanie B, Skirecki, Tomasz, Kox, Matthijs, Winkler, Martin S, Cossarizza, Andrea, Wiersinga, W Joost, van der Poll, Tom, Weigand, Markus A, Cajander, Sara, Giamarellos-Bourboulis, Evangelos J, Lachmann, Gunnar, Girardis, Massimo, Scicluna, Brendon P, Ferrer, Ricard, Payen, Didier, Weis, Sebastian, Torres, Antoni, Bermejo-Martín, Jesús F, Osuchowski, Marcin F, Rubio, Ignacio, Bouma, Hjalmar R · 2025 · The Lancet Respiratory Medicine

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(25)00124-9

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 124

  1. Rudd, 2020, Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study, Lancet, 395, 200, 10.1016/S0140-6736(19)32989-7 · DOI · Paper page
  2. Martinson, 2024, Prevalence of immunosuppression among US adults, JAMA, 331, 880, 10.1001/jama.2023.28019 · doi:10.1001/jama.2023.28019
  3. Tolsma, 2014, Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile, Chest, 146, 1205, 10.1378/chest.13-2618 · DOI
  4. Greenberg, 2018, Hospital volume of immunosuppressed patients with sepsis and sepsis mortality, Ann Am Thorac Soc, 15, 962, 10.1513/AnnalsATS.201710-819OC · doi:10.1513/annalsats.201710-819oc
  5. Vaidie, 2023, Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study, Crit Care, 27, 340, 10.1186/s13054-023-04626-z · DOI
  6. Skevaki, 2015, Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases, Clin Exp Immunol, 180, 165, 10.1111/cei.12578 · DOI · Paper page
  7. Lorenz, 2002, Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock, Arch Intern Med, 162, 1028, 10.1001/archinte.162.9.1028 · DOI · Paper page
  8. Thompson, 2014, Toll-like receptor 1 polymorphisms and associated outcomes in sepsis after traumatic injury: a candidate gene association study, Ann Surg, 259, 179, 10.1097/SLA.0b013e31828538e8 · DOI
  9. Fallerini, 2021, Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study, eLife, 10, 10, 10.7554/eLife.67569 · DOI · Paper page
  10. von Bernuth, 2008, Pyogenic bacterial infections in humans with MyD88 deficiency, Science, 321, 691, 10.1126/science.1158298 · DOI · Paper page
  11. Yao, 2024, The role of inflammasomes in human diseases and their potential as therapeutic targets, Signal Transduct Target Ther, 9, 10, 10.1038/s41392-023-01687-y · DOI · Paper page
  12. Zhong, 2022, NLRP3, NLRC4 and NLRC5 gene polymorphisms associate with susceptibility of pulmonary aspergillosis in non-neutropenic patients, J Clin Med, 11, 10.3390/jcm11071870 · DOI
  13. Faure, 2014, Pseudomonas aeruginosa type-3 secretion system dampens host defense by exploiting the NLRC4-coupled inflammasome, Am J Respir Crit Care Med, 189, 799, 10.1164/rccm.201307-1358OC · DOI · Paper page
  14. Skattum, 2011, Complement deficiency states and associated infections, Mol Immunol, 48, 1643, 10.1016/j.molimm.2011.05.001 · DOI · Paper page
  15. Skokowa, 2017, Severe congenital neutropenias, Nat Rev Dis Primers, 3, 10.1038/nrdp.2017.32 · DOI · Paper page
  16. Resnick, 2012, Morbidity and mortality in common variable immune deficiency over 4 decades, Blood, 119, 1650, 10.1182/blood-2011-09-377945 · doi:10.1182/blood-2011-09-377945
  17. Fischer, 2015, Severe combined immunodeficiencies and related disorders, Nat Rev Dis Primers, 1, 10.1038/nrdp.2015.61 · DOI · Paper page
  18. Vuscan, 2024, Trained immunity: general and emerging concepts, Immunol Rev, 323, 164, 10.1111/imr.13326 · DOI
  19. Lange, 2022, 100 years of Mycobacterium bovis bacille Calmette-Guérin, Lancet Infect Dis, 22, e2, 10.1016/S1473-3099(21)00403-5 · DOI · Paper page
  20. Jansen, 2023, Ex vivo and in vitro monocyte responses do not reflect in vivo immune responses and tolerance, J Innate Immun, 15, 174, 10.1159/000525572 · DOI
  21. Shankar-Hari, 2024, Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies, Lancet Respir Med, 12, 323, 10.1016/S2213-2600(23)00468-X · DOI
  22. Hotchkiss, 2019, Immune checkpoint inhibition in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab, Intensive Care Med, 45, 1360, 10.1007/s00134-019-05704-z · DOI · Paper page
  23. Shankar-Hari, 2020, Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis?, Intensive Care Med, 46, 119, 10.1007/s00134-019-05814-8 · DOI
  24. Kwok, 2023, Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis, Nat Immunol, 24, 767, 10.1038/s41590-023-01490-5 · DOI · Paper page
  25. Brudecki, 2012, Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response, Infect Immun, 80, 2026, 10.1128/IAI.00239-12 · DOI · Paper page
  26. Wolk, 2000, Impaired antigen presentation by human monocytes during endotoxin tolerance, Blood, 96, 218, 10.1182/blood.V96.1.218 · DOI · Paper page
  27. van Amstel, 2023, Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes, Intensive Care Med, 49, 1360, 10.1007/s00134-023-07239-w · DOI
  28. Balintescu, 2023, Glycaemic control and sepsis risk in adults with type 1 diabetes, Diabetes Obes Metab, 25, 1942, 10.1111/dom.15060 · DOI
  29. Balintescu, 2022, Glycemic Control and risk of sepsis and subsequent mortality in type 2 diabetes, Diabetes Care, 45, 127, 10.2337/dc21-1050 · DOI
  30. Abu-Raya, 2020, Maternal immunological adaptation during normal pregnancy, Front Immunol, 11, 10.3389/fimmu.2020.575197 · DOI · Paper page
  31. Wang, 2013, Obesity and risk of sepsis: a population-based cohort study, Obesity, 21, E762, 10.1002/oby.20468 · DOI
  32. Torres, 2022, Sepsis-induced immunosuppression, Annu Rev Physiol, 84, 157, 10.1146/annurev-physiol-061121-040214 · DOI · Paper page
  33. Rubio, 2019, Current gaps in sepsis immunology: new opportunities for translational research, Lancet Infect Dis, 19, e422, 10.1016/S1473-3099(19)30567-5 · DOI · Paper page
  34. Venet, 2018, Advances in the understanding and treatment of sepsis-induced immunosuppression, Nat Rev Nephrol, 14, 121, 10.1038/nrneph.2017.165 · DOI · Paper page
  35. Tangye, 2022, Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee, J Clin Immunol, 42, 1473, 10.1007/s10875-022-01289-3 · DOI · Paper page
  36. Kerner, 2020, Inherited human IFN-γ deficiency underlies mycobacterial disease, J Clin Invest, 130, 3158, 10.1172/JCI135460 · DOI
  37. Constantine, 2019, Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, Immunol Rev, 287, 103, 10.1111/imr.12714 · DOI
  38. Kernan, 2022, Prevalence of pathogenic and potentially pathogenic inborn error of immunity associated variants in children with severe sepsis, J Clin Immunol, 42, 350, 10.1007/s10875-021-01183-4 · DOI
  39. Andreakos, 2022, A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection, Nat Immunol, 23, 159, 10.1038/s41590-021-01030-z · DOI
  40. Tsafaras, 2020, Advantages and limitations of the neonatal immune system, Front Pediatr, 8, 5, 10.3389/fped.2020.00005 · DOI · Paper page
  41. Banerjee, 2017, Age, exercise, and the outcome of sepsis, Crit Care, 21, 286, 10.1186/s13054-017-1840-9 · DOI
  42. Abel, 2024, Human determinants of age-dependent patterns of death from infection, Immunity, 57, 1457, 10.1016/j.immuni.2024.05.020 · DOI
  43. Bastard, 2021, Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths, Sci Immunol, 6, 10.1126/sciimmunol.abl4340 · DOI · Paper page
  44. Puel, 2008, Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6, J Immunol, 180, 647, 10.4049/jimmunol.180.1.647 · DOI · Paper page
  45. Puel, 2010, Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I, J Exp Med, 207, 291, 10.1084/jem.20091983 · DOI · Paper page
  46. Mohammad, 2017, Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis, J Rheumatol, 44, 1468, 10.3899/jrheum.160909 · DOI
  47. Ghembaza, 2020, Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases, Chest, 158, 2323, 10.1016/j.chest.2020.05.558 · DOI
  48. Li, 2023, Association of autoimmune diseases with the occurrence and 28-day mortality of sepsis: an observational and Mendelian randomization study, Crit Care, 27, 476, 10.1186/s13054-023-04763-5 · DOI
  49. Tektonidou, 2019, Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA, Rheumatology, 58, 1794, 10.1093/rheumatology/kez103 · DOI
  50. Tie, 2024, Genetic associations between autoimmune diseases and the risks of severe sepsis and 28-day mortality: a two-sample Mendelian randomization study, Front Med, 11, 10.3389/fmed.2024.1331950 · DOI
  51. Gotur, 2020, Sepsis outcomes in solid organ transplant recipients, Transpl Infect Dis, 22, 10.1111/tid.13214 · DOI
  52. Kalil, 2015, Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study, Clin Infect Dis, 60, 216, 10.1093/cid/ciu789 · DOI
  53. Bahr, 2015, Rapid access to comprehensive care may explain better outcomes in persons with sepsis with solid organ transplant versus those without solid organ transplant, Clin Infect Dis, 60, 1869, 10.1093/cid/civ167 · doi:10.1093/cid/civ167
  54. Podestà, 2021, Mesenchymal stromal cell therapy in solid organ transplantation, Front Immunol, 11, 10.3389/fimmu.2020.618243 · DOI
  55. Donnelly, 2016, Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis, Clin Infect Dis, 63, 186, 10.1093/cid/ciw295 · DOI
  56. Bartoletti, 2018, Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection, Transpl Infect Dis, 20, 10.1111/tid.12930 · doi:10.1111/tid.12930
  57. Kalil, 2015, Reply to Thomason et al and Bahr et al, Clin Infect Dis, 60, 1870, 10.1093/cid/civ169 · DOI
  58. Ackerman, 2023, Effect of sepsis on death as modified by solid organ transplantation, Open Forum Infect Dis, 10, 10.1093/ofid/ofad148 · DOI
  59. Protus, 2022, Sepsis affects kidney graft function and one-year mortality of the recipients in contrast with systemic inflammatory response, Front Med, 9, 10.3389/fmed.2022.923524 · DOI
  60. Boekhoud, 2024, Predictive performance of NEWS and qSOFA in immunocompromised sepsis patients at the emergency department, Infection, 52, 1863, 10.1007/s15010-024-02247-4 · DOI
  61. Richter, 2016, Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis, Ann Rheum Dis, 75, 1667, 10.1136/annrheumdis-2015-207838 · DOI
  62. Kelesidis, 2011, Does rituximab increase the incidence of infectious complications? A narrative review, Int J Infect Dis, 15, e2, 10.1016/j.ijid.2010.03.025 · DOI · Paper page
  63. Athni, 2023, Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab, Ann Allergy Asthma Immunol, 130, 699, 10.1016/j.anai.2023.01.018 · DOI
  64. Hu, 2024, Hospital-treated infections and risk of disability worsening in multiple sclerosis, Ann Neurol, 96, 694, 10.1002/ana.27026 · DOI
  65. Stolk, 2020, Norepinephrine dysregulates the immune response and compromises host defense during sepsis, Am J Respir Crit Care Med, 202, 830, 10.1164/rccm.202002-0339OC · DOI · Paper page
  66. Hensley, 2019, Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations, Crit Care Med, 47, 1310, 10.1097/CCM.0000000000003896 · DOI
  67. Shvetsov, 2021, Association of sepsis mortality with specific cancer sites and treatment type: The Multiethnic Cohort Study, J Pers Med, 11, 146, 10.3390/jpm11020146 · DOI
  68. Williams, 2023, Cancer and sepsis, Clin Sci, 137, 881, 10.1042/CS20220713 · DOI
  69. Sereeaphinan, 2021, Mortality-associated clinical risk factors in patients with febrile neutropenia: a retrospective study, IJID Reg, 1, 5, 10.1016/j.ijregi.2021.09.002 · doi:10.1016/j.ijregi.2021.09.002
  70. Mhaskar, 2014, Colony-stimulating factors for chemotherapy-induced febrile neutropenia, Cochrane Database Syst Rev, 2014
  71. Francois, 2018, Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial, JCI Insight, 3, 10.1172/jci.insight.98960 · DOI · Paper page
  72. MacPhail, 2024, Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study, Crit Care, 28, 148, 10.1186/s13054-024-04932-0 · doi:10.1186/s13054-024-04932-0
  73. Reynolds, 2023, Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis, Blood Adv, 7, 5898, 10.1182/bloodadvances.2023010539 · DOI
  74. Cappell, 2023, Long-term outcomes following CAR T cell therapy: what we know so far, Nat Rev Clin Oncol, 20, 359, 10.1038/s41571-023-00754-1 · DOI · Paper page
  75. Kumar, 2015, Severe sepsis in hematopoietic stem cell transplant recipients, Crit Care Med, 43, 411, 10.1097/CCM.0000000000000714 · doi:10.1097/ccm.0000000000000714
  76. Satwani, 2017, A multicenter study of bacterial blood stream infections in pediatric allogeneic hematopoietic cell transplantation recipients: the role of acute gastrointestinal graft-versus-host disease, Biol Blood Marrow Transplant, 23, 642, 10.1016/j.bbmt.2017.01.073 · DOI
  77. Mori, 2018, Gastrointestinal graft-versus-host disease is a risk factor for postengraftment bloodstream infection in allogeneic hematopoietic stem cell transplant recipients, Biol Blood Marrow Transplant, 24, 2302, 10.1016/j.bbmt.2018.06.002 · DOI
  78. 1981, Pneumocystis pneumonia—Los Angeles, MMWR Morb Mortal Wkly Rep, 30, 250
  79. Grossman, 2002, CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?, Nat Med, 8, 319, 10.1038/nm0402-319 · DOI · Paper page
  80. Barbier, 2020, Management of HIV-infected patients in the intensive care unit, Intensive Care Med, 46, 329, 10.1007/s00134-020-05945-3 · DOI
  81. Huson, 2015, The effect of HIV infection on the host response to bacterial sepsis, Lancet Infect Dis, 15, 95, 10.1016/S1473-3099(14)70917-X · DOI
  82. Cribbs, 2015, Characteristics and outcomes of HIV-infected patients with severe sepsis: continued risk in the post-highly active antiretroviral therapy era, Crit Care Med, 43, 1638, 10.1097/CCM.0000000000001003 · DOI
  83. King, 2015, Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators, JAMA Surg, 150, 343, 10.1001/jamasurg.2014.2257 · DOI
  84. Chaka, 2020, Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting, Int J Infect Dis, 96, 276, 10.1016/j.ijid.2020.04.004 · DOI
  85. Leventogiannis, 2022, Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial, Cell Rep Med, 3
  86. Shankar-Hari, 2020, Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis, Intensive Care Med, 46, 619, 10.1007/s00134-019-05908-3 · DOI
  87. Heffernan, 2021, Host diagnostic biomarkers of infection in the ICU: where are we and where are we going?, Curr Infect Dis Rep, 23, 4, 10.1007/s11908-021-00747-0 · DOI
  88. Svaldi, 2001, Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients, Br J Haematol, 115, 53, 10.1046/j.1365-2141.2001.03083.x · doi:10.1046/j.1365-2141.2001.03083.x
  89. Christ-Crain, 2005, Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study, Crit Care, 9, R816, 10.1186/cc3885 · DOI · Paper page
  90. Liang, 2023, Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis, BMC Infect Dis, 23, 288, 10.1186/s12879-023-08262-4 · DOI
  91. Kumar, 2024, Multidrug-resistant sepsis: a critical healthcare challenge, Antibiotics, 13, 46, 10.3390/antibiotics13010046 · DOI · Paper page
  92. McCreery, 2020, Sepsis in immunocompromised patients without human immunodeficiency virus, J Infect Dis, 222, S156, 10.1093/infdis/jiaa320 · DOI
  93. Di Pasquale, 2019, Prevalence and etiology of community-acquired pneumonia in immunocompromised patients, Clin Infect Dis, 68, 1482, 10.1093/cid/ciy723 · DOI · Paper page
  94. Ramirez, 2020, Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies, Chest, 158, 1896, 10.1016/j.chest.2020.05.598 · DOI · Paper page
  95. Cheng, 2023, Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American Thoracic Society workshop report, Ann Am Thorac Soc, 20, 341, 10.1513/AnnalsATS.202212-1019ST · DOI
  96. Kwakernaak, 2024, Lymfoproliferatieve aandoeningen als uiting van een primaire immuundeficiëntie: herkenning, diagnostiek en behandeling, Ned Tijdschr Hematol, 21, 62
  97. Cajander, 2024, Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine, Lancet Respir Med, 12, 305, 10.1016/S2213-2600(23)00330-2 · DOI · Paper page
  98. Schefold, 2010, Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure, Intensive Care Med, 36, 1810, 10.1007/s00134-010-1965-7 · DOI
  99. Leijte, 2020, Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes, Crit Care, 24, 110, 10.1186/s13054-020-2830-x · DOI
  100. Pfortmueller, 2017, Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers, Intensive Care Med Exp, 5, 49, 10.1186/s40635-017-0163-0 · DOI
  101. Barrios, 2024, Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpot, JCI Insight, 9, 10.1172/jci.insight.175785 · DOI
  102. Llitjos, 2024, Enhancing sepsis biomarker development: key considerations from public and private perspectives, Crit Care, 28, 238, 10.1186/s13054-024-05032-9 · DOI
  103. Li, 2022, Diagnostic value of metagenomic next-generation sequencing for pneumonia in immunocompromised patients, Can J Infect Dis Med Microbiol, 2022, 10.1155/2022/5884568 · DOI
  104. Unterberg, 2023, Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis, Crit Care, 27, 417, 10.1186/s13054-023-04713-1 · DOI
  105. Kalil, 2009, Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit, Crit Care Med, 37, 2350, 10.1097/CCM.0b013e3181a3aa43 · DOI · Paper page
  106. Osawa, 2009, Cytomegalovirus infection in critically ill patients: a systematic review, Crit Care, 13, R68, 10.1186/cc7875 · DOI · Paper page
  107. Lachmann, 2018, Hemophagocytic lymphohistiocytosis: potentially underdiagnosed in intensive care units, Shock, 50, 149, 10.1097/SHK.0000000000001048 · DOI
  108. Brands, 2021, Plasma ferritin as marker of macrophage activation-like syndrome in critically Ill patients with community-acquired pneumonia, Crit Care Med, 49, 1901, 10.1097/CCM.0000000000005072 · DOI
  109. La Rosée, 2019, Recommendations for the management of hemophagocytic lymphohistiocytosis in adults, Blood, 133, 2465, 10.1182/blood.2018894618 · DOI · Paper page
  110. Fan, 2023, Hyperferritinemic sepsis, macrophage activation syndrome, and mortality in a pediatric research network: a causal inference analysis, Crit Care, 27, 347, 10.1186/s13054-023-04628-x · DOI
  111. Davenport, 2016, Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study, Lancet Respir Med, 4, 259, 10.1016/S2213-2600(16)00046-1 · DOI · Paper page
  112. Scicluna, 2017, Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study, Lancet Respir Med, 5, 816, 10.1016/S2213-2600(17)30294-1 · DOI · Paper page
  113. Sweeney, 2018, Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters, Crit Care Med, 46, 915, 10.1097/CCM.0000000000003084 · DOI · Paper page
  114. Baghela, 2022, Predicting sepsis severity at first clinical presentation: the role of endotypes and mechanistic signatures, EBioMedicine, 75, 10.1016/j.ebiom.2021.103776 · DOI · Paper page
  115. Meisel, 2009, Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial, Am J Respir Crit Care Med, 180, 640, 10.1164/rccm.200903-0363OC · DOI · Paper page
  116. Nurmi, 2025, Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial, J Infect, 90, 10.1016/j.jinf.2025.106412 · DOI
  117. Fish, 2022, Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial, Intensive Care Med, 48, 1525, 10.1007/s00134-022-06869-w · DOI
  118. Kotsaki, 2022, ImmunoSep (personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol, BMJ Open, 12, 10.1136/bmjopen-2022-067251 · DOI
  119. 2022, A blood atlas of COVID-19 defines hallmarks of disease severity and specificity, Cell, 185, 916, 10.1016/j.cell.2022.01.012 · DOI · Paper page
  120. Taplitz, 2018, Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update, J Clin Oncol, 36, 3043, 10.1200/JCO.18.00374 · DOI · Paper page
  121. Kamboj, 2024, Vaccination of adults with cancer: ASCO guideline, J Clin Oncol, 42, 1699, 10.1200/JCO.24.00032 · DOI
  122. Oh, 2023, Prior evaluation of nutritional status and mortality in patients with sepsis in South Korea, Nutrients, 15, 10.3390/nu15245040 · DOI
  123. Becker, 2009, Surviving sepsis in low-income and middle-income countries: new directions for care and research, Lancet Infect Dis, 9, 577, 10.1016/S1473-3099(09)70135-5 · DOI
  124. Nates, 2024, Septic shock in the immunocompromised cancer patient: a narrative review, Crit Care, 28, 285, 10.1186/s13054-024-05073-0 · DOI

Metadata

Authors
Deinhardt-Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M., Winkler, M. S., Cossarizza, A., Wiersinga, W. J., van der Poll, T., Weigand, M. A., Cajander, S., Giamarellos-Bourboulis, E. J., Lachmann, G., Girardis, M., Scicluna, B. P., Ferrer, R., Payen, D., Weis, S., Torres, A., Bermejo-Martín, J. F., Osuchowski, M. F., Rubio, I., & Bouma, H. R.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2025-07
Volume
13
Issue
7
Pages
623-637
ISSN
2213-2600
Cited by
64
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. https://app.cochat.ai/papers/10.1016/s2213-2600(25)00124-9
The paper
Deinhardt-Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M., Winkler, M. S., Cossarizza, A., Wiersinga, W. J., van der Poll, T., Weigand, M. A., Cajander, S., Giamarellos-Bourboulis, E. J., Lachmann, G., Girardis, M., Scicluna, B. P., Ferrer, R., Payen, D., Weis, S., . . . Bouma, H. R. (2025). Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(25)00124-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.